GleamWall
中文EN

IVVD Invivyd, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1832038 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.3%
TTM net income YoY-117.7%
TTM EPS YoY15.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-224.4%
Net margin-214.8%
FCF margin-221.0%
EBITDA margin—

Returns

ROE-107.0%
ROA-80.7%
ROIC (approx.)-668.6%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue3.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$15.45M$14.29M$13.74M$17.21M$13.13M$11.79M$11.30M$13.82M
R&D expense$18.74M$29.37M$30.73M$10.05M$8.05M$9.57M$10.64M$17.91M
SG&A expense$30.35M$29.46M$25.12M$18.57M$15.02M$16.59M$16.75M$14.41M
Operating income-$34.68M-$45.82M-$43.14M-$12.55M-$11.02M-$15.06M-$16.92M-$19.23M
Income tax$0$0$0$0$0$0$0$0
Net income-$33.47M-$44.39M-$41.40M-$11.07M-$10.47M-$14.66M-$16.29M-$18.44M
EPS (basic)-0.10-0.14-0.13—-0.06-0.12-0.14—
EPS (diluted)-0.10-0.14-0.13—-0.06-0.12-0.14—
Weighted avg. shares (diluted)322.43M320.44M309.67M—170.17M120.02M119.88M—
Balance sheet
Cash & equivalents$126.40M$160.08M$184.15M$226.69M$84.97M$34.91M$48.08M$69.35M
Receivables$12.19M$11.22M$11.65M$13.92M$9.85M$8.70M$8.56M$10.91M
Inventory————$25.39M$25.44M$25.42M$25.91M
Current assets$147.85M$182.11M$204.91M$247.47M$109.77M$59.28M$75.83M$100.68M
PP&E, net$2.48M$2.18M$1.69M$1.36M$1.26M$1.39M$1.52M$1.51M
Total assets$183.91M$218.88M$241.74M$276.88M$139.16M$89.14M$103.74M$129.51M
Current liabilities$26.81M$31.03M$31.66M$34.16M$44.50M$44.45M$49.59M$61.98M
Total liabilities$33.42M$37.80M$38.69M$35.34M$46.09M$46.35M$49.59M$61.98M
Shareholders' equity$150.48M$181.08M$203.05M$241.54M$93.07M$42.79M$54.15M$67.54M
Shares outstanding295.63M294.76M282.80M281.99M214.41M120.14M119.96M119.84M
Cash flow statement
Operating cash flow-$32.11M-$43.01M-$41.71M-$15.46M-$8.25M-$13.30M-$21.13M-$37.61M
Capital expenditure$585,000$510,000$726,000$0$0$11,000$144,000-$5,000
Free cash flow-$32.70M-$43.52M-$42.44M-$15.46M-$8.25M-$13.31M-$21.27M-$37.60M
Investing cash flow-$585,000-$510,000-$726,000$0$0-$11,000-$144,000$5,000
Financing cash flow$28,000$19.44M-$98,000$157.18M$58.31M$131,000$10,000$77,000
Stock-based compensation$2.74M$2.90M$2.70M$2.56M$3.07M$3.18M$2.83M$3.06M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.